Oziltus (denosumab-mobz, biosimilar to Xgeva)
Named-patient access overview. Oziltus is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
Ask about Oziltus
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Oziltus
Oziltus (denosumab-mobz) is an FDA-approved biosimilar to Xgeva (denosumab), the reference product from Amgen. It is made by Amneal Pharmaceuticals, and the FDA approved it on 19 December 2025. Denosumab is a fully human IgG2 monoclonal antibody that binds and inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), the cytokine that drives osteoclast formation, function, and survival. Blocking RANKL reduces bone resorption and slows the bone-destruction processes that underlie both osteoporosis and certain cancer-related bone disease.
Oziltus is administered by subcutaneous injection on a fixed dosing schedule that depends on the indication. Its FDA-approved uses are prevention of skeletal-related events in patients with multiple myeloma or bone metastases from solid tumors, giant cell tumor of bone in adults and skeletally mature adolescents when surgery is not suitable, and hypercalcemia of malignancy that does not respond to bisphosphonates. The labelled dose is 120 mg by subcutaneous injection every 4 weeks, with extra 120 mg doses on days 8 and 15 of the first month for giant cell tumor of bone and hypercalcemia of malignancy.
For international patients, Oziltus is sourced by Reserve Meds from a US-licensed pharmaceutical wholesale partner with full serial traceability and may be accessible via Named Patient Program or personal-import pathways depending on destination country.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How Reserve Meds coordinates Oziltus
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Oziltus for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Oziltus is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Oziltus in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), how quotes work, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Oziltus
Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.